News and Events  Press Releases

• SCYNEXIS to Lead Discussion of Software System With Local Global Health Group
• SCYNEXIS and Trevena Announce Strategic Collaboration to Enhance Discovery of Biased GPCR Ligands
• SCYNEXIS Presents In Vitro Toxicity Study Suggesting that SCY-635 is Unique in the Cyclophilin Inhibitor Class
• SCYNEXIS' SCY-635 Demonstrates Impressive Barrier to Resistance in HCV Treatment
• SCYNEXIS Announces Acceptance of Abstracts Related to its Hepatitis C Clinical Candidate, SCY-635, for Presentation at 45th Annual Meeting of the European Association for the Study of the Liver
• SCYNEXIS to Present at the Canaccord Adams' Hepatitis C Conference
• SCYNEXIS, Inc. Receives Milestone Payment from Collaboration with Merck & Co., Inc.
• SCYNEXIS cGMP Facilities Audited by FDA - No Form 483 Observations Issued
• SCYNEXIS Receives Merial Research Collaboration Milestone Payment
• SCYNEXIS’ SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents
• SCYNEXIS Receives Milestone Payment in Oncology Collaboration with Merck & Co., Inc.
• SCYNEXIS and Medicines for Malaria Venture Sign HEOS® Agreement
• SCYNEXIS’ SCY-635 Demonstrates Clinically Relevant Single-agent Results in a Phase 1b Study in Adults with HCV
• First Candidate from SCYNEXIS’ Novel Cyclophilin Inhibitor Platform, SCY 635, Establishes Proof of Concept in HCV-Infected Adults
• SCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness
• SCYNEXIS to Present Preclinical HCV Data on Novel Cyclophillin Inhibitor SCY-635 at AASLD Annual Meeting
• SCYNEXIS Convenes Renowned Scientists for Symposium on the Therapeutic Promise of Cyclophilin Inhibitors
• SCYNEXIS, Inc. Completes $13.5 Million Financing
• Scynexis Receives Merial Research Collaboration Milestone Payment
• SCYNEXIS and DNDi Enter Landmark Multi-Year Agreement to Identify Drug Candidates to Treat Sleeping Sickness
• Merial-SCYNEXIS Research Collaboration Expanded
• SCYNEXIS, Inc. Receives Preclinical Milestone Payment In Collaboration with Merck
• SCYNEXIS announces research agreement with Merck for discovery of novel oncology agents
• SCYNEXIS announces new board chairman and new board member appointments of well-known pharmaceutical executives
• SCYNEXIS Europe is now Selcia following spin off from SCYNEXIS, Inc
• Teijin Pharma and SCYNEXIS Sign Research Agreement
• SCYNEXIS, Inc. Selected As a Primary Research Partner for Merial
• ADHEREX AND SCYNEXIS SIGN AGREEMENT TO ACCELERATE DESIGN OF SMALLMOLECULE CADHERIN ANTAGONISTS
• Norak Biosciences And SCYNEXIS Announce Chemistry Collaboration
• SCYNEXIS Signs A Drug Discovery Deal With Mitsubishi Pharma
• SCYNEXIS Announces Broadening of Research Agreement With Roche For Discovery Of Novel Central Nervous System And Metabolic Disease Agents
• MERCK, SCYNEXIS Announce Broadening Of Research Collaboration For Discovery Of Novel Anti-Infective Agents
• SCYNEXIS Announces Research Collaboration with Roche For Discovery of Novel Central Nervous System and Metabolic Disease Agents
• SCYNEXIS, Inc. Announces Research Collaboration with Merck & Co., Inc. For Discovery Of Novel Anti-infective Agents
• SCYNEXIS Completes $29 million New Round of Investment
• SCYNEXIS Closes First Round of Funding

Copyright © 2010. SCYNEXIS, INC